Prelude Therapeutics (PRLD) Projected to Post Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11. The business had revenue of $4.00 million during the quarter. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Stock Down 3.4 %

Shares of NASDAQ:PRLD traded down $0.03 on Friday, reaching $0.89. 85,025 shares of the company's stock were exchanged, compared to its average volume of 269,298. The business's 50-day moving average is $0.75 and its two-hundred day moving average is $1.00. Prelude Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $6.80. The firm has a market capitalization of $50.10 million, a price-to-earnings ratio of -0.50 and a beta of 1.35.

Analysts Set New Price Targets

A number of brokerages have issued reports on PRLD. JMP Securities reissued a "market outperform" rating and issued a $4.00 target price on shares of Prelude Therapeutics in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Prelude Therapeutics in a report on Tuesday, April 8th.

Insider Buying and Selling at Prelude Therapeutics

In other Prelude Therapeutics news, insider Andrew Combs bought 100,000 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were purchased at an average cost of $0.69 per share, for a total transaction of $69,000.00. Following the transaction, the insider now directly owns 480,123 shares in the company, valued at $331,284.87. The trade was a 26.31 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Krishna Vaddi purchased 47,500 shares of Prelude Therapeutics stock in a transaction on Wednesday, March 12th. The shares were acquired at an average price of $0.71 per share, with a total value of $33,725.00. Following the transaction, the chief executive officer now directly owns 1,214,775 shares in the company, valued at $862,490.25. This trade represents a 4.07 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 822,500 shares of company stock valued at $568,475 in the last ninety days. Company insiders own 62.80% of the company's stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.